PMC:1310901 / 2263-2419 JSONTXT

{"project":"bionlp-st-ge-2016-reference-eval","denotations":[{"id":"T2680","span":{"begin":15,"end":27},"obj":"Protein"},{"id":"T2691","span":{"begin":29,"end":34},"obj":"Protein"}],"relations":[{"id":"R2110","pred":"equivalentTo","subj":"T2691","obj":"T2680"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"events-check-again","denotations":[{"id":"T2518","span":{"begin":15,"end":27},"obj":"Protein"},{"id":"T2519","span":{"begin":29,"end":34},"obj":"Protein"}],"relations":[{"id":"R2024","pred":"equivalentTo","subj":"T2519","obj":"T2518"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"sentences","denotations":[{"id":"T1056","span":{"begin":0,"end":156},"obj":"Sentence"},{"id":"T14","span":{"begin":0,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"2_test","denotations":[{"id":"16396836-8605319-76538164","span":{"begin":151,"end":152},"obj":"8605319"},{"id":"16396836-10219069-76538165","span":{"begin":153,"end":154},"obj":"10219069"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"pmc-enju-pas","denotations":[{"id":"T1183","span":{"begin":0,"end":9},"obj":"NN"},{"id":"T1184","span":{"begin":10,"end":14},"obj":"IN"},{"id":"T1185","span":{"begin":15,"end":25},"obj":"NN"},{"id":"T1186","span":{"begin":26,"end":27},"obj":"NN"},{"id":"T1187","span":{"begin":28,"end":29},"obj":"-LRB-"},{"id":"T1188","span":{"begin":29,"end":34},"obj":"NN"},{"id":"T1189","span":{"begin":34,"end":35},"obj":"-RRB-"},{"id":"T1190","span":{"begin":36,"end":44},"obj":"VB"},{"id":"T1191","span":{"begin":45,"end":53},"obj":"NN"},{"id":"T1192","span":{"begin":54,"end":56},"obj":"IN"},{"id":"T1193","span":{"begin":57,"end":60},"obj":"NN"},{"id":"T1194","span":{"begin":61,"end":69},"obj":"NN"},{"id":"T1195","span":{"begin":70,"end":73},"obj":"CC"},{"id":"T1196","span":{"begin":74,"end":76},"obj":"VB"},{"id":"T1197","span":{"begin":77,"end":87},"obj":"VB"},{"id":"T1198","span":{"begin":88,"end":92},"obj":"IN"},{"id":"T1199","span":{"begin":93,"end":94},"obj":"DT"},{"id":"T1200","span":{"begin":95,"end":103},"obj":"JJ"},{"id":"T1201","span":{"begin":104,"end":115},"obj":"JJ"},{"id":"T1202","span":{"begin":116,"end":124},"obj":"NN"},{"id":"T1203","span":{"begin":125,"end":127},"obj":"IN"},{"id":"T1204","span":{"begin":128,"end":132},"obj":"CD"},{"id":"T1205","span":{"begin":132,"end":133},"obj":"NN"},{"id":"T1206","span":{"begin":134,"end":136},"obj":"IN"},{"id":"T1207","span":{"begin":137,"end":140},"obj":"NN"},{"id":"T1208","span":{"begin":141,"end":149},"obj":"NN"},{"id":"T1209","span":{"begin":150,"end":151},"obj":"-LRB-"},{"id":"T1210","span":{"begin":151,"end":154},"obj":"CD"},{"id":"T1211","span":{"begin":154,"end":155},"obj":"-RRB-"}],"relations":[{"id":"R851","pred":"arg1Of","subj":"T1183","obj":"T1184"},{"id":"R852","pred":"arg1Of","subj":"T1183","obj":"T1190"},{"id":"R853","pred":"arg1Of","subj":"T1183","obj":"T1196"},{"id":"R854","pred":"arg2Of","subj":"T1183","obj":"T1197"},{"id":"R855","pred":"arg2Of","subj":"T1186","obj":"T1184"},{"id":"R856","pred":"arg1Of","subj":"T1186","obj":"T1185"},{"id":"R857","pred":"arg1Of","subj":"T1186","obj":"T1187"},{"id":"R858","pred":"arg2Of","subj":"T1188","obj":"T1187"},{"id":"R859","pred":"arg3Of","subj":"T1189","obj":"T1187"},{"id":"R860","pred":"arg1Of","subj":"T1190","obj":"T1195"},{"id":"R861","pred":"arg2Of","subj":"T1191","obj":"T1190"},{"id":"R862","pred":"arg1Of","subj":"T1191","obj":"T1192"},{"id":"R863","pred":"arg2Of","subj":"T1194","obj":"T1192"},{"id":"R864","pred":"arg1Of","subj":"T1194","obj":"T1193"},{"id":"R865","pred":"arg2Of","subj":"T1197","obj":"T1195"},{"id":"R866","pred":"arg2Of","subj":"T1197","obj":"T1196"},{"id":"R867","pred":"arg1Of","subj":"T1197","obj":"T1198"},{"id":"R868","pred":"arg2Of","subj":"T1202","obj":"T1198"},{"id":"R869","pred":"arg1Of","subj":"T1202","obj":"T1199"},{"id":"R870","pred":"arg1Of","subj":"T1202","obj":"T1200"},{"id":"R871","pred":"arg1Of","subj":"T1202","obj":"T1201"},{"id":"R872","pred":"arg1Of","subj":"T1202","obj":"T1203"},{"id":"R873","pred":"arg2Of","subj":"T1205","obj":"T1203"},{"id":"R874","pred":"arg1Of","subj":"T1205","obj":"T1204"},{"id":"R875","pred":"arg1Of","subj":"T1205","obj":"T1206"},{"id":"R876","pred":"arg2Of","subj":"T1208","obj":"T1206"},{"id":"R877","pred":"arg1Of","subj":"T1208","obj":"T1207"},{"id":"R878","pred":"arg1Of","subj":"T1208","obj":"T1209"},{"id":"R879","pred":"arg2Of","subj":"T1210","obj":"T1209"},{"id":"R880","pred":"arg3Of","subj":"T1211","obj":"T1209"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"bionlp-st-ge-2016-spacy-parsed","denotations":[{"id":"T1806","span":{"begin":0,"end":9},"obj":"NNP"},{"id":"T1807","span":{"begin":10,"end":14},"obj":"IN"},{"id":"T1808","span":{"begin":15,"end":25},"obj":"NN"},{"id":"T1809","span":{"begin":26,"end":27},"obj":"NN"},{"id":"T1810","span":{"begin":28,"end":29},"obj":"-LRB-"},{"id":"T1811","span":{"begin":29,"end":34},"obj":"NNP"},{"id":"T1812","span":{"begin":34,"end":35},"obj":"-RRB-"},{"id":"T1813","span":{"begin":36,"end":44},"obj":"NNS"},{"id":"T1814","span":{"begin":45,"end":53},"obj":"NN"},{"id":"T1815","span":{"begin":54,"end":56},"obj":"IN"},{"id":"T1816","span":{"begin":57,"end":60},"obj":"NNP"},{"id":"T1817","span":{"begin":61,"end":69},"obj":"NNS"},{"id":"T1818","span":{"begin":70,"end":73},"obj":"CC"},{"id":"T1819","span":{"begin":74,"end":76},"obj":"VBZ"},{"id":"T1820","span":{"begin":77,"end":87},"obj":"VBN"},{"id":"T1821","span":{"begin":88,"end":92},"obj":"IN"},{"id":"T1822","span":{"begin":93,"end":94},"obj":"DT"},{"id":"T1823","span":{"begin":95,"end":103},"obj":"JJ"},{"id":"T1824","span":{"begin":104,"end":115},"obj":"JJ"},{"id":"T1825","span":{"begin":116,"end":124},"obj":"NN"},{"id":"T1826","span":{"begin":125,"end":127},"obj":"IN"},{"id":"T1827","span":{"begin":128,"end":129},"obj":"CD"},{"id":"T1828","span":{"begin":130,"end":132},"obj":"CD"},{"id":"T1829","span":{"begin":132,"end":133},"obj":"NN"},{"id":"T1830","span":{"begin":134,"end":136},"obj":"IN"},{"id":"T1831","span":{"begin":137,"end":140},"obj":"NNP"},{"id":"T1832","span":{"begin":141,"end":149},"obj":"NNS"},{"id":"T1833","span":{"begin":150,"end":151},"obj":"-LRB-"},{"id":"T1834","span":{"begin":151,"end":154},"obj":"CD"},{"id":"T1835","span":{"begin":154,"end":155},"obj":"-RRB-"},{"id":"T1836","span":{"begin":155,"end":156},"obj":"."}],"relations":[{"id":"R1429","pred":"nsubj","subj":"T1806","obj":"T1813"},{"id":"R1430","pred":"prep","subj":"T1807","obj":"T1806"},{"id":"R1431","pred":"compound","subj":"T1808","obj":"T1809"},{"id":"R1432","pred":"pobj","subj":"T1809","obj":"T1807"},{"id":"R1433","pred":"punct","subj":"T1810","obj":"T1811"},{"id":"R1434","pred":"appos","subj":"T1811","obj":"T1809"},{"id":"R1435","pred":"punct","subj":"T1812","obj":"T1806"},{"id":"R1436","pred":"ROOT","subj":"T1813","obj":"T1813"},{"id":"R1437","pred":"dobj","subj":"T1814","obj":"T1813"},{"id":"R1438","pred":"prep","subj":"T1815","obj":"T1814"},{"id":"R1439","pred":"compound","subj":"T1816","obj":"T1817"},{"id":"R1440","pred":"pobj","subj":"T1817","obj":"T1815"},{"id":"R1441","pred":"cc","subj":"T1818","obj":"T1813"},{"id":"R1442","pred":"auxpass","subj":"T1819","obj":"T1820"},{"id":"R1443","pred":"conj","subj":"T1820","obj":"T1813"},{"id":"R1444","pred":"prep","subj":"T1821","obj":"T1820"},{"id":"R1445","pred":"det","subj":"T1822","obj":"T1825"},{"id":"R1446","pred":"amod","subj":"T1823","obj":"T1825"},{"id":"R1447","pred":"amod","subj":"T1824","obj":"T1825"},{"id":"R1448","pred":"pobj","subj":"T1825","obj":"T1821"},{"id":"R1449","pred":"prep","subj":"T1826","obj":"T1825"},{"id":"R1450","pred":"pobj","subj":"T1827","obj":"T1826"},{"id":"R1451","pred":"nummod","subj":"T1828","obj":"T1829"},{"id":"R1452","pred":"npadvmod","subj":"T1829","obj":"T1820"},{"id":"R1453","pred":"prep","subj":"T1830","obj":"T1829"},{"id":"R1454","pred":"compound","subj":"T1831","obj":"T1832"},{"id":"R1455","pred":"pobj","subj":"T1832","obj":"T1830"},{"id":"R1456","pred":"punct","subj":"T1833","obj":"T1832"},{"id":"R1457","pred":"appos","subj":"T1834","obj":"T1832"},{"id":"R1458","pred":"punct","subj":"T1835","obj":"T1820"},{"id":"R1459","pred":"punct","subj":"T1836","obj":"T1813"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"bionlp-st-ge-2016-reference-tees","denotations":[{"id":"T2571","span":{"begin":15,"end":27},"obj":"Protein"},{"id":"T2572","span":{"begin":29,"end":34},"obj":"Protein"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"bionlp-st-ge-2016-reference","denotations":[{"id":"T1007","span":{"begin":15,"end":27},"obj":"Protein"},{"id":"T1008","span":{"begin":29,"end":34},"obj":"Protein"}],"relations":[{"id":"R749","pred":"equivalentTo","subj":"T1008","obj":"T1007"}],"namespaces":[{"prefix":"_base","uri":"http://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"bionlp-st-ge-2016-uniprot","denotations":[{"id":"T1675","span":{"begin":29,"end":34},"obj":"P01562"}],"namespaces":[{"prefix":"_base","uri":"http://www.uniprot.org/uniprot/"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}

{"project":"test2","denotations":[{"id":"T955","span":{"begin":15,"end":27},"obj":"Protein"},{"id":"T956","span":{"begin":29,"end":34},"obj":"Protein"}],"relations":[{"id":"R722","pred":"equivalentTo","subj":"T956","obj":"T955"}],"text":"Treatment with interferon α (IFN-α) prolongs survival of CML patients and is associated with a complete cytogenetic response in 5–33% of CML patients (1,2)."}